<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240711062391N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-08-17</date_registration>
      <primary_sponsor>Arak University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effect of virtual reality and aromatherapy with lavender on anxiety caused by bone marrow biopsy</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of virtual reality and aromatherapy with lavender on anxiety caused by bone marrow biopsy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>132</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/78145</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this research, random blocks will be used in order to hide the randomized allocation (concealment) and establish balance (balance) during and after the study. In this way, based on the sample size, people will be randomly placed in blocks of 3. Random sequence generation will be done by block building method by Sealed envelope software. In the mentioned software, the total sample size and the number of groups are entered into the software. The randomization unit in the mentioned software is a person. The output of the software is a grouped list that randomly distributes the number of samples in three groups. According to the mentioned list, patients are distributed in three groups according to the time of visit so that the sample size reaches the required number in each group. The randomized list in the form of an Excel file will only be available to the researcher (M-H).</study_design>
      <phase>3</phase>
      <hc_freetext>Anxiety caused by bone marrow biopsy.</hc_freetext>
      <i_freetext>Intervention 1: first Intervention group: After randomization, a questionnaire related to demographic characteristics and Spielberger anxiety will be completed. Then people will be subjected to aromatherapy intervention during the waiting time and for 12-20 minutes. In the aromatherapy group, 2 drops of lavender essential oil (Provided by Ellis Pharmaceutical Company, Kazeroon, Iran) will be poured with a dropper on a 10 x 10 cm gas and will be connected to a distance of 20 cm from the subject's nose and on their shirt. They will be asked to inhale the aromatherapy through natural breathing for 12-20 minutes. Intervention 2: second Intervention group: Intervention group: After randomization, a questionnaire related to demographic characteristics and Spielberger anxiety will be completed. Then people will be subjected to virtual reality intervention during the waiting time and for 12-20 minutes. The equipment used for the virtual reality technique will be a virtual reality device (Remax-RT-V03 audio visual glasses with internal memory) and headset, with the help of which, patients are exposed to the sound and pleasant scenes of nature with high quality. In this way, conditions are provided for them to experience more relaxation by diverting their thoughts and immersing themselves in a pleasant and enjoyable environment instead of focusing on the surgical process. Intervention 3: Control group: After randomization, a questionnaire related to demographic characteristics and Spielberger's anxiety will be completed. People in the control group spend the same waiting period without intervention and under usual conditions until they are called according to their turn.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Its release schedule is not yet known</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Erfan Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahamat 2 Alley, Shahamat St., Moshaver Town, Arak, IRAN</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3818887174</zip>
        <telephone>+98 86 3368 8149</telephone>
        <email>erfanmohammadiuniversity@gmail.com</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Moloud Farmahini Farahani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Blue wing, Nursing school, Basij Square, Arak, Markazi Province, Iran</address>
        <city>Arak</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3848176941</zip>
        <telephone>+98 86 3383 8246</telephone>
        <email>mfarmahini@arakmu.ac.ir</email>
        <affiliation>Arak University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Willingness to participate in the study
Age between 18 and 60 years
Having the necessary eyesight and hearing
Having the ability to read and write in Persian
Not suffering from severe psychiatric disorders such as psychotic disorders, bipolar mood disorder, panic disorder and depression.
Not having a history of allergy to aromatic substances, proven problems in the sense of smell, previous allergy to lavender and an allergy</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Withdrawal and unwillingness to continue participating in any stage of the study according to the patient's choice and decision
Occurrence of any special medical condition that is contrary to the continued participation of individuals</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F06.4</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anxiety disorder due to known physiological condition</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>first Intervention group: After randomization, a questionnaire related to demographic characteristics and Spielberger anxiety will be completed. Then people will be subjected to aromatherapy intervention during the waiting time and for 12-20 minutes. In the aromatherapy group, 2 drops of lavender essential oil (Provided by Ellis Pharmaceutical Company, Kazeroon, Iran) will be poured with a dropper on a 10 x 10 cm gas and will be connected to a distance of 20 cm from the subject's nose and on their shirt. They will be asked to inhale the aromatherapy through natural breathing for 12-20 minutes.</i_keyword>
      <i_keyword>second Intervention group: Intervention group: After randomization, a questionnaire related to demographic characteristics and Spielberger anxiety will be completed. Then people will be subjected to virtual reality intervention during the waiting time and for 12-20 minutes. The equipment used for the virtual reality technique will be a virtual reality device (Remax-RT-V03 audio visual glasses with internal memory) and headset, with the help of which, patients are exposed to the sound and pleasant scenes of nature with high quality. In this way, conditions are provided for them to experience more relaxation by diverting their thoughts and immersing themselves in a pleasant and enjoyable environment instead of focusing on the surgical process.</i_keyword>
      <i_keyword>Control group: After randomization, a questionnaire related to demographic characteristics and Spielberger's anxiety will be completed. People in the control group spend the same waiting period without intervention and under usual conditions until they are called according to their turn.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety. Timepoint: Before and after the intervention. Method of measurement: The State-Trait Anxiety Inventory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Arak University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-06-23</approval_date>
        <contact_name>Ethics committee of Arak University of Medical Sciences</contact_name>
        <contact_address>Arak University of Medical Sciences, Basij St, Sardasht, Arak Arak Markazi Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
